Movers and SHAKERS
Lineage Cell Therapeutics (LCTX)
Early VAC2 Data Shows Promise
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
VAC2 preliminary Phase 1 study results. Lineage disclosed data from the Phase 1 clinical study of VAC2 for the treatment of non-small cell lung cancer (NSCLC), sponsored by partner Cancer Research UK (CR UK). The results showed induction of immune responses (significant induction of antigen-specific T cells) in four patients dosed to date. In addition, one patient (1/4 patients) experienced a radiological response (a measure of tumor response to therapy).
What does it mean? We believe this preliminary data is positive and shows clues of potential clinical activity. While the data is encouraging, it is still early in the process and was assessed in a small population (four patients). Lineage used its option to reacquire VAC2 to further develop the asset in the clinic, announced in May 2020. The company plans to initiate a Phase 1/2 clinical trial ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.